Growing and Innovating: The State of U.S. Biopharma Contract Manufacturing

The demand for biopharma contract manufacturing services is at an all-time high. So how did we get here, and where is the industry going?

The increased reliance on biopharma contract manufacturing organizations (CMOs) has been driven by various cost-saving and efficiency-building incentives for biotechnology and pharmaceutical companies, including:

1. Lower production costs
2. Reduced manufacturing footprint
3. Dynamic manufacturing capabilities
4. Increased speed to market
5. Reduced risk
6. Fewer capital expenditures
7. Access to specialty equipment and processes

All these factors, plus the increased demand for biologics, are contributing to a projected near doubling of the North American biopharmaceutical contract manufacturing market over the next several years, from a valuation of $6.2 billion in 2019 to an anticipated $11.75 billion by 2027.¹